News Takeda builds in cancer with monster $11.4bn Innovent deal Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.
News ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role New trial data back the use of Boehringer's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.
News Kelun gets world-first approval for TROP2 ADC Kelun-Biotech has picked up another world-first approval for its TROP2-targeting ADC sac-TMT in non-small cell lung cancer.
News Mixed data from lung cancer trials on show at WCLC Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.
News Boehringer back in cancer with Hernexeos approval Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for lung cancer therapy Hernexeos.
News GSK suffers a setback with its TIM-3 programme GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3.
News J&J swoops on cancer biotech Halda with $3bn takeover deal Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy Halda Therapeutics and its RIPTAC anticancer platform.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.